The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity

Vaccine

Volumn 15, Issue 2, 1997, Pages 179-186

  Laferrière, Craig A ^a,b   Sood, Ramesh K ^a,c   De Muys, Jean Marc ^a   Michon, Francis ^a,d   Jennings, Harold J ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c Nabi Biopharmaceuticals   (United States)

^d North American Vaccine Inc   (United States)

Author keywords

Glycoconjugate vaccine; Immunogenicity; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; OPSONIZATION; PERITONEUM CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; RABBIT; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ANIMALS; HL-60 CELLS; HUMANS; OPSONIN PROTEINS; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; RABBITS; REPRODUCIBILITY OF RESULTS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE-ACTIVITY RELATIONSHIP; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0031081674     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00148-X     Document Type: Article

References (40)

1. 1 Dixon, J.M.S. Chairman, National Advisory Committee on Immunization. Pneumococcal Vaccine. In: Canadian Immunization Guide, 3rd Edn. Minister of Supplies and Services. Cat. No. H49-8/1989E, 1989, pp. 85-88
2. 2 Ismaeel, N.A. Serotype distribution, antimicrobial susceptibility, and clinical character of Streptococcus pneumoniae isolates. Microbios. 1993, 74, 233-240
3. 3 Lee, C.-J. and Wang, T.R. Pneumococcal infection and immunization in children. Crit. Rev. Micrbiol. 1994, 20, 1-12
4. 4 Hirschmann, J.V. and Lipsky, B.A. The pneumococcal vaccine after 15 years of use. Arch. Intern. Med. 1994, 154, 373-377
5. 5 Fine, M.J., Smith, M.A., Carson, C.A. et al. Efficacy of pneumococcal vaccination in adults, a meta-analysis of randomized controlled trials. Arch. Intern. Med. 1994, 154, 2666-2677
6. 6 Fedson, D.S., Shapiro, E.D., LaForce, F.M., Mufson, M.A., Spika, S. and Breiman, F. Pneumococcal Vaccine after 15 years of use, another view. Arch. Intern. Med. 1994, 154, 2531-2535
7. 7 Jennings, H.J. and Sood, R.K. Synthetic glycoconjugates as human vaccines. In: Neoglycoconjugtes. Preparation and Applications (Eds Lee, Y.C. and Lee, R.T.). Academic Press, New York, 1994, pp. 325-371
8. 8 Anderson, P. and Betts, R. Human adult immunogenicity of protein coupled pneumococcal capsular antigens of serotypes prevalent in otitis media. Pediatr. Infect. Dis, J. 1989, 8, S50-S53
9. 9 Vella, P.P., Marburg, S., Staub, J.M. et al. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide type 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex. Infect. Immun. 1992, 60, 4977-4983
10. 10 Giebink, G.S., Koskela, M., Vella, P.P., Harris, M. and Lee, C.T. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J. Infect. Dis. 1993, 167, 347-355
11. 11 Kuo, J., Douglas, M., Ree, H.K. and Lindberg, A.A. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines. Infect. Immun. 1995, 63, 2706-2713
12. 12 De Velasco, E., Verheul, A.F.M., Dekker, H.A.T. et al. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Infect. Immun. 1994, 62, 799-808
13. 13 De Velasco, E., Dekker, H.A.T., Verheul, A.F.M., Feldman, R.G., Verhoef, J. and Snippe, H. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J. Infect. Dis. 1995, 172, 562-565
14. 14 Paton, J.C., Lock, R.A., Lee, C.-J. et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect. Immun. 1991, 59, 2297-2304
15. 15 Arndt, B. and Porro, M. Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumonias. In: Immunobiology of Proteins and Peptides VI (Ed. Atassi, M.Z.). Plenum Press, New York, 1991, pp. 129-148
16. 16 Schneerson, R., Levi, L., Robbins, J.B., Bryla, D.M., Schiffman, G. and Lagergard, T. Synthesis of conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect. Immun. 1992, 60, 3528
17. 17 Paoletti, L.C., Wessels, M.R., Michon, F., Jennings, H.J. and Kasper, D.L. Group B Streptococcus type III glycoconjugate vaccines. Trends Glycosci. Glycotechnol. 1992, 4, 269-278
18. 18 Sorensen, E.B.S. Pneumococcal polysaccharide antigens: capsules and C-polysaccharide, an immunochemical study. Dan. Med. Bull. 1995, 42, 47-53
19. 19 Vioarsson, G., Jonsdottir, I., Jonsson, S. and Valdimarsson, H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 1994, 170, 592-599
20. 20 Musher, D.M., Watson, D.A. and Baughn, R.E. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?. J. Infect. Dis. 1990, 161, 736-740
21. 21 Kenny, J.J., Guelde, G., Fischer, R.T. and Largo, D.L. Induction of phosphorylcholine-specific antibodies in X-linked immunodeficient mice: in vivo protection against a Streptococcus pneumoniae challenge. Int. Immun. 1994, 6, 561
22. 22 Szu, S.C., Schneerson, R. and Robbins, J.B. Rabbit antibodies to cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect. Immun. 1986, 54, 448
23. 23 Kulakowska, M., Brisson, J.-R., Griffith, D.W., Young, N.M. and Jennings, H.J. High resolution NMR spectroscopic analysis of the C-polysaccharide of Streptococcus pneumoniae. Can. J. Chem. 1993, 71, 644-648
24. 24 Geelen, S., Bhattacharyya, C. and Tuomanen, E. The cell wall mediates pneumococcal attachment and cytopathology in human endothelial cells. Infect. Immun. 1993, 61, 1538-1543
25. 25 Borch, R.F., Bernstein, M.D. and Durst, H.D. The cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93, 2897-2904
26. 26 Fox, J.D. and Robyt, J.F. Miniaturization of three carbohydrate analyses using a microsample plate reader. Analyt. Biochem. 1991, 195, 93-96
27. 27 Kabat, E.A. Methyl pentose determination. In: Experimental Immunology (Eds Kabat, E.A. and Mayer, M.). Thomas, Springfield, IL, 1964, pp. 538-541
28. 28 Dische, Z. A new specific color reaction for hexuronic acids. J. Biol. Chem. 1947, 167, 189-198
29. 29 Jennings, H.J. and Lugowski, C. Immunochemistry of group A, B and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immun. 1981, 127, 1011
30. 30 Dubois, M., Giles, K.A., Hamilton, J.K., Rebers, P.A. and Smith, F. Colorimetric method for the determination of sugars and related substances. Analyt. Chem. 1956, 28, 350-356
31. 31 Smith, P.K., Krohn, R.I., Hermanson, G.T. et al. Measurement of protein using bicinchoninic acid. Analyt. Biochem. 1985, 150, 76-85
32. 32 Reeves, R.E. and Goebel, W.F. Chemoimmunologic studies on the soluble specific substrate of pneumococcus. V. The structure of the type III polysaccharide. J. Biol. Chem. 1941, 139, 511-519
33. 33 Rebers, P.A. and Heidelberger, M. The structure of the specific polysaccharide of type Vl pneumococcus. II. The repeating unit. J. Am. Chem. Soc. 1961, 83, 3056-3059
34. 34 Lugowski, C. and Jennings, H.J. Structural determination of the capsular polysaccharide from Streptococcus pneumoniae type 18C (56). Carbohydr. Res. 1984, 131, 119-129
35. 35 Jennings, H.J., Rosell, K.G. and Carlo, D.J. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19 (19F). Can. J. Chem. 1980, 58, 1069-1074
36. 36 Richards, J.C. and Perry, M.B. Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F. Biochem. Cell. Biol. 1988, 66, 758-771
37. 37 Guckian, J.C., Christensen, G.D. and Fine, D.P. The role of opsonins in recovery from experimental pneumococcal pneumonia. J. Infect. Dis. 1980, 142, 175-190
38. 38 Winkelstein, J.A. The role of complement in the host's defense against Streptococcus pneumoniae. Rev. Infect. Dis. 1981, 3, 289-298
39. 39 Whitin, J.C. and Anderson, P. Dimethyl formamide (DMF)-activated HL-60 cells in a convenient assay for antibodies opsonic for pneumococcus. Pediatr. Res. 1993, 4, 187A
40. 40 Marques, M.B., Kasper, D.L., Shroft, A., Michon, F., Jennings, H.J. and Wessels, M.R. Functional activities of antibodies to the group B polysaccharide of group B Streptococcus elicited by a polysaccharide-protein conjugate vaccine. Infect. Immun. 1994, 62, 1593-1599